Milk derived colloid as a novel drug delivery carrier for breast cancer

Masamichi Hayashi, Nissim Silanikove, Xiaofei Chang, Rajani Ravi, Vui Pham, Gilson Baia, Keren Paz, Mariana Brait Rodrigues De Oliveira, David Sidransky, Wayne Martin Koch

Research output: Contribution to journalArticle

Abstract

Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component ‘MDC’ from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.

Original languageEnglish (US)
Pages (from-to)1184-1193
Number of pages10
JournalCancer Biology and Therapy
Volume16
Issue number8
DOIs
StatePublished - 2015

Fingerprint

Drug Carriers
Colloids
Milk
Doxorubicin
Breast Neoplasms
Neoplasms
Nanoparticles
Heterografts
Pharmaceutical Preparations
Growth
Triple Negative Breast Neoplasms
Cell Line
Drug Delivery Systems
Drug Resistance
Melanoma
Breast
Safety
Drug Therapy
Research

Keywords

  • Breast cancer
  • Doxil
  • Doxorubicin
  • Milk
  • Nanoparticle
  • Xenograft

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Milk derived colloid as a novel drug delivery carrier for breast cancer. / Hayashi, Masamichi; Silanikove, Nissim; Chang, Xiaofei; Ravi, Rajani; Pham, Vui; Baia, Gilson; Paz, Keren; Brait Rodrigues De Oliveira, Mariana; Sidransky, David; Koch, Wayne Martin.

In: Cancer Biology and Therapy, Vol. 16, No. 8, 2015, p. 1184-1193.

Research output: Contribution to journalArticle

Hayashi, Masamichi ; Silanikove, Nissim ; Chang, Xiaofei ; Ravi, Rajani ; Pham, Vui ; Baia, Gilson ; Paz, Keren ; Brait Rodrigues De Oliveira, Mariana ; Sidransky, David ; Koch, Wayne Martin. / Milk derived colloid as a novel drug delivery carrier for breast cancer. In: Cancer Biology and Therapy. 2015 ; Vol. 16, No. 8. pp. 1184-1193.
@article{9656ca9568014baa95bd2b55205af9bc,
title = "Milk derived colloid as a novel drug delivery carrier for breast cancer",
abstract = "Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component ‘MDC’ from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.",
keywords = "Breast cancer, Doxil, Doxorubicin, Milk, Nanoparticle, Xenograft",
author = "Masamichi Hayashi and Nissim Silanikove and Xiaofei Chang and Rajani Ravi and Vui Pham and Gilson Baia and Keren Paz and {Brait Rodrigues De Oliveira}, Mariana and David Sidransky and Koch, {Wayne Martin}",
year = "2015",
doi = "10.1080/15384047.2015.1056416",
language = "English (US)",
volume = "16",
pages = "1184--1193",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Milk derived colloid as a novel drug delivery carrier for breast cancer

AU - Hayashi, Masamichi

AU - Silanikove, Nissim

AU - Chang, Xiaofei

AU - Ravi, Rajani

AU - Pham, Vui

AU - Baia, Gilson

AU - Paz, Keren

AU - Brait Rodrigues De Oliveira, Mariana

AU - Sidransky, David

AU - Koch, Wayne Martin

PY - 2015

Y1 - 2015

N2 - Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component ‘MDC’ from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.

AB - Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component ‘MDC’ from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.

KW - Breast cancer

KW - Doxil

KW - Doxorubicin

KW - Milk

KW - Nanoparticle

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84983381032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983381032&partnerID=8YFLogxK

U2 - 10.1080/15384047.2015.1056416

DO - 10.1080/15384047.2015.1056416

M3 - Article

C2 - 26046946

AN - SCOPUS:84983381032

VL - 16

SP - 1184

EP - 1193

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -